Vor Biopharma Competitors

Vor Biopharma (NYSE:VOR) and Seer (NASDAQ:SEER) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vor Biopharma and Seer, as provided by MarketBeat.com.

Vor Biopharma currently has a consensus target price of $48.20, suggesting a potential upside of 60.13%. Seer has a consensus target price of $68.00, suggesting a potential upside of 33.73%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Seer.

Earnings and Valuation

This table compares Vor Biopharma and Seer's top-line revenue, earnings per share and valuation.

Profitability

This table compares Vor Biopharma and Seer's net margins, return on equity and return on assets.

Summary

Vor Biopharma beats Seer on 3 of the 3 factors compared between the two stocks.

Vor Biopharma (NYSE:VOR) and Nuvation Bio (NYSE:NUVB) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vor Biopharma and Nuvation Bio, as provided by MarketBeat.com.

Vor Biopharma currently has a consensus target price of $48.20, suggesting a potential upside of 60.13%. Nuvation Bio has a consensus target price of $17.40, suggesting a potential upside of 73.48%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Vor Biopharma.

Earnings and Valuation

This table compares Vor Biopharma and Nuvation Bio's top-line revenue, earnings per share and valuation.

Profitability

This table compares Vor Biopharma and Nuvation Bio's net margins, return on equity and return on assets.

Summary

Nuvation Bio beats Vor Biopharma on 3 of the 3 factors compared between the two stocks.

Vor Biopharma (NYSE:VOR) and ImmunityBio (NASDAQ:IBRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Vor Biopharma and ImmunityBio, as provided by MarketBeat.com.

Vor Biopharma currently has a consensus target price of $48.20, suggesting a potential upside of 60.13%. ImmunityBio has a consensus target price of $25.00, suggesting a potential upside of 43.84%. Given Vor Biopharma's higher probable upside, analysts plainly believe Vor Biopharma is more favorable than ImmunityBio.

Earnings and Valuation

This table compares Vor Biopharma and ImmunityBio's top-line revenue, earnings per share and valuation.

Profitability

This table compares Vor Biopharma and ImmunityBio's net margins, return on equity and return on assets.

Summary

Vor Biopharma beats ImmunityBio on 2 of the 3 factors compared between the two stocks.

Immunocore (NASDAQ:IMCR) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation and institutional ownership.

Earnings & Valuation

This table compares Immunocore and Vor Biopharma's gross revenue, earnings per share (EPS) and valuation.

Analyst Recommendations

This is a breakdown of recent recommendations for Immunocore and Vor Biopharma, as provided by MarketBeat.

Immunocore currently has a consensus price target of $54.3333, suggesting a potential upside of 42.05%. Vor Biopharma has a consensus price target of $48.20, suggesting a potential upside of 60.13%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Immunocore.

Profitability

This table compares Immunocore and Vor Biopharma's net margins, return on equity and return on assets.

Summary

Vor Biopharma beats Immunocore on 2 of the 3 factors compared between the two stocks.

BioAtla (NASDAQ:BCAB) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares BioAtla and Vor Biopharma's gross revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent ratings for BioAtla and Vor Biopharma, as provided by MarketBeat.com.

BioAtla presently has a consensus price target of $58.00, indicating a potential upside of 21.49%. Vor Biopharma has a consensus price target of $48.20, indicating a potential upside of 60.13%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than BioAtla.

Profitability

This table compares BioAtla and Vor Biopharma's net margins, return on equity and return on assets.

Cullinan Oncology (NASDAQ:CGEM) and Vor Biopharma (NYSE:VOR) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, institutional ownership and profitability.

Earnings and Valuation

This table compares Cullinan Oncology and Vor Biopharma's gross revenue, earnings per share (EPS) and valuation.

Analyst Ratings

This is a summary of recent ratings for Cullinan Oncology and Vor Biopharma, as provided by MarketBeat.com.

Cullinan Oncology presently has a consensus price target of $48.25, indicating a potential upside of 37.07%. Vor Biopharma has a consensus price target of $48.20, indicating a potential upside of 60.13%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Cullinan Oncology.

Profitability

This table compares Cullinan Oncology and Vor Biopharma's net margins, return on equity and return on assets.

Summary

Vor Biopharma beats Cullinan Oncology on 2 of the 3 factors compared between the two stocks.